Lonza Group AG Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche Holding AG Call Transcript
Ladies and gentlemen, welcome to the Lonza Investor Conference Call and Live Webcast. I am Sandra, the Chorus Call operator. (Operator Instructions) The conference is being recorded. (Operator Instructions) The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Mr. Albert M. Baehny, CEO at interim and Chairman of the Board of Directors. Please go ahead, sir.
Thank you for the introduction. Good morning, good afternoon, and thanks to you all for joining the short update call about our agreement to acquire the Vacaville site from Roche. I'm joined today by our CFO, Philippe Deecke; and the President of our Biologics division, Jean-Christophe Hyvert. We will share a few details of the acquisition, then take some time to answer your questions. Let me provide a short overview of the transaction.
Today, we have signed an agreement with Roche to acquire the Genentech large-scale biologics facility in Vacaville, California, for USD 1.2
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |